THERALOGICS, INC.

Company Information

Company Name
THERALOGICS, INC.
Address
P.O.Box 12613
Research Triangle Park
Durham, NC, -
Phone
n/a
URL
n/a
DUNS
170945617
Number of Employees
2

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
STTR Phase I
$1,137,540.00
4
STTR Phase II
$2,281,812.00
2
Chart code to be here

Award List

  1. Inhibition of IkK to treat lethal Graft-vs.-Host Disease

    Amount: $885,556.00

    DESCRIPTION (provided by applicant): Allogeneic stem cell transplantation (allo-SCT) is potentially curative therapy for a patients suffering from leukemia, lymphoma and multiple myeloma. However, th ...

    STTR Phase II 2008 Department of Health and Human Services
  2. Blockade of NF-kappaB for Prevention/Treatment of GVHD

    Amount: $244,488.00

    DESCRIPTION (provided by applicant): Allogeneic stem cell transplantation (allo-SCT) is potentially curative therapy for a patients suffering from leukemia, lymphoma and multiple myeloma. However, the ...

    STTR Phase I 2006 Department of Health and Human Services
  3. Validation of a Novel NF-KB Inhibitor in Murine IBD

    Amount: $216,950.00

    DESCRIPTION (provided by applicant): The human inflammatory bowel diseases (IBDs), Crohn's disease (CD) and ulcerative colitis (UC), affect over one million Americans. Until recently, therapies for th ...

    STTR Phase I 2006 Department of Health and Human Services
  4. NF-kB Inhibition of Lung Ischemia Repurfusion Injury

    Amount: $255,627.00

    DESCRIPTION (provided by applicant): Ischemia-reperfusion injury (IRI) is a major problem in many clinical scenarios, including myocardial infarction and stroke. IRI is also a major problem in organ t ...

    STTR Phase I 2009 Department of Health and Human Services
  5. Evaluation of NBD Peptides as an Adjunct Therapy for the Treatment of Non-Hodgkin

    Amount: $420,475.00

    DESCRIPTION (provided by applicant): The NF-?B family of transcription factors plays a central role in the regulation of lymphocyte proliferation, differentiation and survival. Aberrant constitutive a ...

    STTR Phase I 2010 Department of Health and Human Services
  6. Validation of a Novel NF-kB Inhibitor in Inflammatory Bowel Disease

    Amount: $1,396,256.00

    DESCRIPTION (provided by applicant): The human inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, affect over one million Americans and significant unmet medical needs sti ...

    STTR Phase II 2012 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government